Overview
Mixed neuroendocrine and non-neuroendocrine neoplasm of the pancreas, often called MiNEN (pronounced 'my-nen'), is a rare type of pancreatic cancer. It is also sometimes called mixed adenoneuroendocrine carcinoma, or MANEC. What makes this tumor unusual is that it contains two very different types of cancer cells growing together in the same tumor. One part behaves like a neuroendocrine tumor — a cancer that starts in hormone-producing cells. The other part behaves like a more common type of pancreatic cancer, such as an adenocarcinoma, which starts in gland-forming cells. By definition, each component makes up at least 30% of the tumor. The pancreas is a gland in your abdomen that helps with digestion and controls blood sugar. When a MiNEN develops there, it can disrupt both of these functions. Because the tumor has two different cell types, it can be harder to diagnose and treat than a single-type pancreatic cancer. Symptoms often include abdominal pain, unexplained weight loss, jaundice (yellowing of the skin and eyes), nausea, and changes in blood sugar. Treatment usually involves surgery when possible, combined with chemotherapy. Because this cancer is so rare, treatment decisions are often made by a team of specialists at a major cancer center. The prognosis depends heavily on how advanced the cancer is at diagnosis and which component of the tumor is more aggressive.
Also known as:
Key symptoms:
Abdominal or upper belly painUnexplained weight lossYellowing of the skin or eyes (jaundice)Nausea and vomitingLoss of appetiteNew or worsening diabetes or blood sugar problemsPale or greasy stoolsDark urineFatigue and weaknessA lump or mass felt in the abdomenBack painBloating or feeling full quickly
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
3 eventsEuropean Institute of Oncology
Metrogel: FDA approved
Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableMetrogel
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas.
Community
No community posts yet. Be the first to share your experience with Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas.
Start the conversation →Latest news about Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What stage is my cancer, and has it spread beyond the pancreas?,Which part of my tumor — the neuroendocrine or the other type — is more aggressive, and how does that affect my treatment?,Am I a candidate for surgery, and what would that involve?,What chemotherapy regimen do you recommend, and why?,Should my tumor be tested for specific genetic mutations that might guide treatment?,Are there any clinical trials I might be eligible for?,What support services — such as nutrition counseling, pain management, or mental health support — are available to me?
Common questions about Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas
What is Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas?
Mixed neuroendocrine and non-neuroendocrine neoplasm of the pancreas, often called MiNEN (pronounced 'my-nen'), is a rare type of pancreatic cancer. It is also sometimes called mixed adenoneuroendocrine carcinoma, or MANEC. What makes this tumor unusual is that it contains two very different types of cancer cells growing together in the same tumor. One part behaves like a neuroendocrine tumor — a cancer that starts in hormone-producing cells. The other part behaves like a more common type of pancreatic cancer, such as an adenocarcinoma, which starts in gland-forming cells. By definition, each
How is Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas inherited?
Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas typically begin?
Typical onset of Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas?
Yes — 1 recruiting clinical trial is currently listed for Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas?
6 specialists and care centers treating Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.